Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

This publication has 33 references indexed in Scilit:

• Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18
  Clinical and Vaccine Immunology, 2005
• Immunogenicity and Reactogenicity of a Novel Vaccine for Human Papillomavirus 16: A 2-Year Randomized Controlled Clinical Trial
  Mayo Clinic Proceedings, 2005
• Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer
  Cancer Epidemiology, Biomarkers & Prevention, 2005
• A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine
  Vaccine, 2004
• Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women
  Vaccine, 2004
• Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine
  Vaccine, 2004
• Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
  New England Journal of Medicine, 2003
• Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay
  Clinical and Vaccine Immunology, 2003
• Neutralization of Human Papillomavirus Type 11 (HPV‐11) by Serum from Women Vaccinated with Yeast‐Derived HPV‐11 L1 Virus‐like Particles: Correlation with Competitive Radioimmunoassay Titer
  The Journal of Infectious Diseases, 2001
• Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
  JNCI Journal of the National Cancer Institute, 1995